BUY PLIAGLIS ONLINE AS AN ALTERNATIVE TO EMLA. FDA APPROVED
PLIAGLIS is the first and only FDA-approved topical anesthetic that combines the highest concentrations of two powerful ingredients, Lidocaine and Tetracaine, for fast onset and lasting effect.
PLIAGLIS is indicated to produce local dermal anaesthesia (numbing) on intact skin prior to dermatological procedures, such as dermal filler injections, botox injections, mesotherapy, laser resurfacing etc.
Pliaglis is favored by many aesthetic practitioners thanks to being well-tolerated and having mild side effects when used as recommended compared to other topical local anesthetics. In addition, lidocaine/tetracaine cream has several other unique attributes:
- Ease of application – a flat-surfaced tool, such as a metal spatula or tongue depressor, can be used to apply a uniform thin (1 mm) layer of the cream;
- Self-occluding formulation – it’s applied as a cream and when exposed to air, it forms a mask on the skin. Most of other prescribed topical anesthetics are applied to the skin and then occluded with plastic wrap to enhance cutaneous absorption;
- Ease of removal – the formed on the skin mask easily peels off;
- Ability for use in skin folds and provide adequate anesthesia at peripheral skin areas.
ADMINISTRATION OF PLIAGLIS
For dermatological procedures such as pulsed-dye laser therapy, laser-assisted hair removal, non-ablative laser facial resurfacing, dermal filler injections and vascular access, PLIAGLIS should be applied onto intact skin at a thickness of approximately 1mm for 30 minutes (approximately 1.3 g of cream per 10 cm2). After the required time, the peel must then be removed from the skin prior to the procedure.
For dermatological procedures such as laser-assisted tattoo removal, and laser leg vein ablation, PLIAGLIS should be applied onto intact skin at a thickness of approximately 1mm for 60 minutes (approximately 1.3 g of cream per 10 cm2). After the required time, the peel must then be removed from the skin prior
|Surface Area of Treatment Site (cm2)||Approximate weight of Pliaglis Dispensed (g)|
|10||1.3||2 fingertip units|
|50||6.5||Half content of a 15g tube|
|100||13||Full content of a 15g tube|
|200||26||Full content of a 30g tube|
|400||52||Full content of two 30g tubes|
The maximum application area should not exceed 400 cm2.
PLIAGLIS should be used with caution in patients with hepatic, renal and cardiac impairment.
The safety and efficacy of PLIAGLIS in children and adolescents aged up to 18 years have not been established. Therefore, the use of Pliaglis is not recommended in children and adolescents.
PLIAGLIS should never be applied with fingers. It should only be applied with a flat surfaced tool such as a spatula. Hands should be washed immediately after removing and disposal of the peel.
ADDITIONAL INFORMATION ABOUT PLIAGLIS
Active Compositions: Each gram contains 70 mg of Lidocaine and 70 mg of Tetracaine.
Volume & Packaging: 15 g tube or 30 g tube.
Accessory: Package Insert only.
Storage Conditions: Do not store above 25℃ and do not freeze.
PLIAGLIS is manufactured in Europe by DIFA Cooper.